Skip to content
New: free dose calculator with 14 peptide presets. No signup.
Peptides Academy

Subcutaneous Injection for Peptides

Subcutaneous injection delivers peptides into the fat layer beneath the skin, where slow absorption from the subcutaneous depot provides sustained plasma levels. This is the default administration route for the majority of self-administered peptides, from BPC-157 to semaglutide.

How It Works

SC injection uses a 27–31 gauge needle, 0.5 inches (12.7 mm) in length, inserted at a 45–90 degree angle into a pinched fold of skin and subcutaneous fat. Insulin syringes (29–31G, 0.5 mL) are the standard for peptide SC injection due to their fine gauge, short needle, and accurate low-volume graduation.

Common injection sites are the abdomen (2+ inches from the navel), outer thigh, and upper arm (posterior-lateral). The abdomen provides the most consistent absorption for most peptides. Rotate injection sites systematically to prevent lipodystrophy — the formation of fat tissue irregularities from repeated injection at the same location.

Technique: clean the injection site with an alcohol swab and let it dry. Pinch a fold of skin and fat between thumb and forefinger. Insert the needle at 45° (lean individuals) or 90° (adequate subcutaneous fat). Inject slowly over 5–10 seconds. Hold for 5–10 seconds before withdrawing. Do not massage the site — this accelerates absorption and may alter the pharmacokinetic profile.

For GLP-1 agonists (semaglutide, tirzepatide), manufacturer-supplied auto-injector pens simplify the process with pre-set doses and hidden needles.

Benefits

Simple technique suitable for self-administration at home
Less painful than intramuscular injection — shorter, finer needles
Good bioavailability for most peptides (60–80%)
Slow, sustained absorption from the subcutaneous depot
Lower risk of complications compared to IM or IV routes
Compatible with small injection volumes (0.1–1 mL)
Avoids first-pass liver metabolism that would destroy most peptides orally

Recommended Products (8)

BPC-157
healing body-protection

BPC-157

Research-Grade

A 15-amino-acid peptide fragment derived from gastric juice protein BPC, studied extensively in animal models for tissue healing and gut integrity.

CJC-1295 + Ipamorelin
growth hormone-secretagogue

CJC-1295 + Ipamorelin

Research-Grade

The most widely used GHRH + GHRP stack — CJC-1295 extends GHRH half-life while Ipamorelin selectively amplifies GH pulses without disturbing cortisol or prolactin.

CJC-1295 (no-DAC) 2–5 mg/vial; Ipamorelin 2–5 mg/vial
Ipamorelin
growth hormone-secretagogue

Ipamorelin

Research-Grade

The most selective GHRP (growth-hormone-releasing peptide) — amplifies GH pulses via ghrelin/GHSR receptor without meaningful cortisol, prolactin, or aldosterone crosstalk.

Semaglutide
glp 1-analog

Semaglutide

Ozempic / Wegovy / Rybelsus

Long-acting GLP-1 receptor agonist — FDA-approved for type-2 diabetes and chronic weight management, landmark for its ~15% mean weight reduction in STEP trials.

Ozempic: 0.25–2 mg weekly; Wegovy: up to 2.4 mg weeklyFDA-approved (Ozempic, Wegovy, Rybelsus)
Sermorelin
growth hormone-secretagogue

Sermorelin

Research-Grade

The first synthetic GHRH analog approved for clinical use — GHRH (1-29) NH₂, the minimum active sequence. Shorter-acting than tesamorelin or CJC-1295.

Previously FDA-approved (Geref, discontinued)Available via compounding in US
TB-500 (Thymosin β4 Fragment)
healing body-protection

TB-500 (Thymosin β4 Fragment)

Research-Grade

Synthetic fragment of Thymosin β4 investigated for actin-binding, cell migration, and tissue repair across muscle, cornea, and cardiac models.

Tesamorelin
growth hormone-secretagogue

Tesamorelin

Egrifta

FDA-approved synthetic GHRH analog indicated for HIV-associated lipodystrophy, studied for visceral adipose tissue reduction and cognitive endpoints.

2 mg per daily dose (per FDA labeling)FDA-approved (Egrifta)
Tirzepatide
tirzepatide class

Tirzepatide

Mounjaro / Zepbound

First-in-class dual GIP/GLP-1 receptor agonist — SURMOUNT trials showed ~20% mean weight reduction and superior A1c control versus semaglutide.

2.5–15 mg weekly (escalating)FDA-approved (Mounjaro T2D, Zepbound obesity)

Frequently Asked Questions

Does the injection site matter for SC peptide injections?
Yes, but the differences are usually modest. Abdominal SC injection generally provides faster and more consistent absorption than the thigh for most peptides. For semaglutide specifically, FDA labeling states that abdomen, thigh, and upper arm are interchangeable. For GH-releasing peptides (ipamorelin, sermorelin), the abdomen is preferred to avoid injecting near exercising muscles.
What gauge needle is best for peptide SC injections?
29–31 gauge, 0.5 inch (12.7 mm). Standard insulin syringes meet this specification. Finer gauges (30–31G) are less painful but harder to draw up viscous solutions. For most reconstituted peptide solutions, 29G is the best balance of comfort and practicality.
How do I prevent bruising at injection sites?
Inject slowly, don't aspirate (unnecessary for SC), withdraw the needle at the same angle it entered, and apply light pressure (not massage) with a clean swab. Rotate sites systematically. Avoid injecting into visible veins. Some bruising is normal and harmless — it does not affect peptide absorption.
Is IM better than SubQ for peptides?
Rarely. Most peptides have been pharmacokinetically characterized via SC injection. IM accelerates absorption but is more painful, requires longer needles, and offers no therapeutic advantage for standard peptide protocols. IM is preferred only for larger injection volumes (>2 mL) or specific peptides like Cerebrolysin.

Other peptide Treatments

Browse All peptide Products

Search

Search across products, blog posts, wiki articles, and more.